Evaluation of the optimal LNCaP prostate tumour developmental stage to be assessed by 99mTc-HYNIC-βAla-Bombesin(7-4) in an experimental model
详细信息 查看全文
- 作者：Leonardo Lima Fuscaldi (1)
André Luís Branco de Barros (1)
Caiubi Rodrigues de Paula Santos (1)
Cristina Maria de Souza (2)
Geovanni Dantas Cassali (2)
M?nica Cristina de Oliveira (1)
Simone Odília Antunes Fernandes (1)
Valbert Nascimento Cardoso (1) - 关键词：Bombesin ; Radiopeptide ; LNCaP prostate tumour ; Molecular imaging ; Histopathological analysis
- 刊名：Journal of Radioanalytical and Nuclear Chemistry
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：300
- 期：2
- 页码：801-807
- 全文大小：3,425 KB
- 参考文献：1. Cancer incidence and mortality worldwide (2010) GLOBOCAN 2008 v2.0, Lyon. http://globocan.iarc.fr. Accessed 30 Jan 2013
2. Schottelius M, Wester H (2009) Molecular imaging targeting peptide receptors. Methods 48:161-77 meth.2009.03.012" target="_blank" title="It opens in new window">CrossRef
3. Weiner RE, Thakur ML (2002) Radiolabeled peptides in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 57:749-63 CrossRef
4. Ferro-Flores G, Ramírez FM, Meléndez-Alafort L, Santos-Cuevas CL (2010) Peptides for in vivo target-specific cancer imaging. Mini Rev Med Chem 10:87-7 CrossRef
5. de Barros ALB, Mota LG, Soares DCF, Coelho MMA, Oliveira MC, Cardoso VN (2011) Tumor bombesin analog loaded long-circulating and pH-sensitive liposomes as tool for tumor identification. Bioorg Med Chem Lett 21:7373-375 mcl.2011.10.016" target="_blank" title="It opens in new window">CrossRef
6. de Barros ALB, Mota LG, Ferreira CA, Corrêa NCR, Góes AM, Oliveira MC, Cardoso VN (2013) 99mTc-labeled bombesin analog for breast cancer identification. J Radioanal Nucl Chem 295:2083-090 CrossRef
7. Lears KA, Ferdani R, Liang K, Zheleznyak A, Andrews R, Sherman CD, Achilefu S, Anderson CJ, Rogers BE (2011) In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer. J Nucl Med 52:470-77 med.110.082826" target="_blank" title="It opens in new window">CrossRef
8. Mansi R, Wang X, Forrer F, Waser B, Cescato R, Graham K, Borkowski S, Reubi JC, Maecke HR (2011) Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours. Eur J Nucl Med Mol Imaging 38:97-07 CrossRef
9. Yu Z, Carlucci G, Ananias HJK, Dierckx RAJO, Liu S, Helfrich W, Wang F, de Jong IJ, Elsinga PH (2013) Evaluation of a technetium-99m labeled bombesin homodimer for GRPR imaging in prostate cancer. Amino Acids 44:543-53 CrossRef
10. Schroeder RPJ, van Weerden WM, Bangma C, Krenning EP, de Jong M (2009) Peptide receptor imaging of prostate cancer with radiolabelled bombesin analogues. Methods 48:200-04 meth.2009.04.002" target="_blank" title="It opens in new window">CrossRef
11. Kong F, Zhang Y, Young DP, Yu D, Yang DJ (2013) Development of 99mTc-EC-tyrosine for early detection of breast cancer tumor response to the anticancer drug melphalan. Acad Radiol 20:41-1 CrossRef
12. Yang DJ, Kim C, Schechter NR, Azhdarinia A, Yu D, Oh C, Bryant JL, Won J, Kim EE, Podoloff DA (2003) Imaging with 99mTc-ECDG targeted at the multifunctional glucose transport system: feasibility study with rodents. Radiology 226:465-73 CrossRef
13. de Barros ALB, Mota LG, Ferreira CA, de Oliveira MC, de Góes AM, Cardoso VN (2010) Bombesin derivative radiolabeled with technetium-99m as agent for tumor identification. Bioorg Med Chem Lett 20:6182-184 mcl.2010.08.124" target="_blank" title="It opens in new window">CrossRef
14. de Barros ALB, Mota LG, Ferreira CA, Cardoso VN (2012) Kit formulation for 99mTc-labeling of HYNIC-βAla-Bombesin(7-4). Appl Radiat Isot 70:2440-445 CrossRef
15. Lambrecht FY, Durkan K, Bayrak E (2010) Labeling bombesin-like peptide with 99mTc via hydrazinonicotinamide: description of optimized radiolabeling conditions. J Radioanal Nucl Chem 284:539-45 CrossRef
16. Lambrecht FY, Durkan K, ?zgür A, Gündüz C, Avc? ?B, Susluer SY (2013) In vitro evaluation of 99mTc-EDDA/tricine-HYNIC-Q-Litorin in gastrin-releasing peptide receptor positive tumor cell lines. J Drug Target 21:383-88 CrossRef
17. Emonds KM, Swinnen JV, Mortelmans L, Mottaghy FM (2009) Molecular imaging of prostate cancer. Methods 48:193-99 meth.2009.03.021" target="_blank" title="It opens in new window">CrossRef
18. Feldman BJ, Feldman D (2001) The development of androgen-independent prostate cancer. Nat Rev 1:34-5 CrossRef
19. Grigoryev DN, Long BJ, Njar VCO, Brodie AHM (2000) Pregnenolone stimulates LNCaP prostate cancer cell growth via the mutated androgen receptor. J Steroid Biochem Mol Biol 75:1-0 CrossRef
20. Xie Y, Wolff DW, Lin M, Tu Y (2007) Vasoactive intestinal peptide transactivates the androgen receptor through a protein kinase A-dependent extracellular signal-regulated kinase pathway in prostate cancer LNCaP cells. Mol Pharmacol 72:73-5 mol.107.033894" target="_blank" title="It opens in new window">CrossRef
21. Yu S, Lai K, Xia S, Chang H, Chang C, Yeh S (2009) The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer. Asian J Androl 11:39-8 CrossRef
22. Maddalena ME, Fox J, Chen J, Feng W, Cagnolini A, Linder KE, Tweedle MF, Nunn AD, Lantry LE (2009) 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression. J Nucl Med 50:2017-024 med.109.064444" target="_blank" title="It opens in new window">CrossRef
23. National Formulary (USP 34-NF 29) (2011) US Pharmacopeia
24. Horoszewicz JS, Leong SS, Kawinski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP (1983) LNCaP model of human prostatic carcinoma. Cancer Res 43:1809-818
25. Chua TC, Yao P, Akther J, Morris DL (2010) Impact of tumor angiogenesis in peritoneal mesothelioma after radical cytoreduction and hyperthermic intraperitoneal chemotherapy. Pathol Oncol Res 16:217-22 CrossRef
26. Jun HY, Yin H, Kim S, Park SH, Kim HS, Yoon K (2010) Visualization of tumor angiogenesis using MR imaging contrast agent Gd-DTPA-anti-VEGF receptor 2 antibody conjugate in a mouse tumor model. Korean J Radiol 11:449-56 CrossRef
27. Ghosh K, Thodeti CK, Dudley AC, Mammoto A, Klagsbrun M, Ingber DE (2008) Tumor-derived endothelial cells exhibit aberrant Rho-mediated mechanosensing and abnormal angiogenesis in vitro. PNAS 105:11305-1310 CrossRef
28. Faintuch BL, Teodoro R, Duatti A, Muramoto E, Faintuch S, Smith CJ (2008) Radiolabeled bombesin analogs for prostate cancer diagnosis: preclinical studies. Nucl Med Biol 35:401-11 medbio.2008.02.005" target="_blank" title="It opens in new window">CrossRef
29. Shi J, Jia B, Liu Z, Yang Z, Yu Z, Chen K, Chen X, Liu S, Wang F (2008) 99mTc-labeled Bombesin(7-4)NH2 with favorable properties for SPECT imaging of colon cancer. Bioconjug Chem 19:1170-178 CrossRef
30. Phillips WT (1999) Delivery of gamma-imaging agents by liposomes. Adv Drug Delivery Rev 37:13-2 CrossRef - 作者单位：Leonardo Lima Fuscaldi (1)
André Luís Branco de Barros (1)
Caiubi Rodrigues de Paula Santos (1)
Cristina Maria de Souza (2)
Geovanni Dantas Cassali (2)
M?nica Cristina de Oliveira (1)
Simone Odília Antunes Fernandes (1)
Valbert Nascimento Cardoso (1)
1. Faculdade de Farmácia, Universidade Federal de Minas Gerais, Av. Ant?nio Carlos, 6627, Belo Horizonte, Minas Gerais, 31270-901, Brazil
2. Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Av. Ant?nio Carlos, 6627, Belo Horizonte, Minas Gerais, 31270-901, Brazil - ISSN：1588-2780
文摘
The lymph node carcinoma of the prostate (LNCaP) cell line is widely used in prostate cancer diagnostic studies. However, the optimal developmental stage during which to assess LNCaP prostate tumours by in vivo molecular imaging has not been established. This study aimed to assess LNCaP prostate tumours by scintigraphic imaging using technetium-99m (99mTc)-2-hydrazinonicotinamide (HYNIC)-beta-alanine (βAla)-Bombesin(7-4) at different stages of tumour development and to compare each developmental stage using histopathological analysis. 99mTc-HYNIC-βAla-Bombesin(7-4) (7.4?MBq) was injected into LNCaP prostate tumour-bearing mice after 15, 20 or 25?days of tumour inoculation. Scintigraphic images were obtained 1 and 4?h following radiopeptide injection and tumour tissues were obtained for histopathological analysis. Tumours were not observed by scintigraphic imaging after 15?days of inoculation, but after 20 and 25?days of inoculation, tumours were visualised, with a tumour-to-muscle ratio of 2.14 at 4?h after the radiopeptide injection into mice with 25-day tumours. Histopathological analysis showed that the amount of collagen fibres in the stroma was inversely proportional to the stage of tumour development, whereas the intensity of vascular proliferation was directly proportional to the tumour stage; this explains radiopeptide localisation in LNCaP cells and improved visualisation of the 25-day tumours. In conclusion, the results showed that 25-day tumours presented the most appropriate features for radiopeptide accumulation in LNCaP cells, suggesting that they are in the best stage of tumour development to be assessed by scintigraphic imaging using 99mTc-HYNIC-βAla-Bombesin(7-4).